American Association for Cancer Research

Program

 

SUNDAY, MARCH 21

Educational Sessions

1:00 p.m.-3:00 p.m.

  • Session 1: Omics and Bioinformatics

    Chairperson: Olli-P. Kallioniemi, Finland Institute for Molecular Medicine, Helsinki, Finland

    From canceromics research to personalized cancer therapies
    Olli-P. Kallioniemi

    The role of informatics in translational research: The interplay of epidemiology, clinical studies, and discovery research
    Jacob Koehler, Eli Lilly and Company, Indianapolis, IN, USA

    Title to be announced
    John N. Weinstein, UT M. D. Anderson Cancer Center, Houston, TX

  • Session 2: Translational and Clinical Trial Design

    Chairperson: Eric H. Rubin, Merck Research Laoratories, North Wales, PA, USA

    Approaches to solving the combinations problem in oncology therapeutics
    Eric H. Rubin

    Translational genomics in clinical trials
    Carlos M. Caldas, Cancer Research UK, Cambridge, United Kingdom

    Title to be announced
    Laura J. van't Veer, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Educational Sessions

3:15 p.m.-5:15 p.m.

  • Session 3: GWAS vs. Systems Biology

    Chairperson: Stephen J. Chanock, National Cancer Institute, Bethesda, MD, USA

    Genome-wide association studies in cancer: Insights in cancer etiology
    Stephen J. Chanock

    Understanding melanoma using GWAS and systems biology
    Julia A. Newton Bishop, University of Leeds, Leeds, United Kingdom

    Etiological clues from breast cancer GWAS
    Montserrat Garcia-Closas, NCI-DCEG, Rockville, MD, USA

  • Session 4: Functional Imaging: Getting Beyond FDG-PET

    Chairperson: E. G. Elisabeth de Vries, University Medical Center Groningen, Groningen, The Netherlands

    Functional imaging: Beyond FDG
    Patricia M. Price, Christie Hospital NHS Trust, Manchester, United Kingdom

    Functional imaging: Getting beyond FDG-PET
    E. G. Elisabeth de Vries

    PET tracer for therapy monitoring
    Hans-Jürgen Wester, Technische Universität München, Munich, Germany

Keynote Session

Chairpersons: Alexander M.M. Eggermont, Erasmus Medical Center, Rotterdam, The Netherlands and Susan E. Bates, National Cancer Institute, Bethesda, MD, USA
6:00 p.m.-7:00 p.m.

Finding mechanisms and biomarkers of drug resistance in cancer
René Bernards, Netherlands Cancer Institute, Amsterdam, The Netherlands

Opening Reception

7:00 p.m.-9:00 p.m.

 

MONDAY, MARCH 22

Plenary Session 1: Translational Medicine in Breast Cancer Research

Chairperson: Nadia Harbeck, University of Cologne, Cologne, Germany
8:30 a.m.–10:30 a.m.

Targeting PI3K in breast cancer
José Baselga, Vall d'Hebron University Hospital, Barcelona, Spain

Genomic architecture characterizes tumor progression paths and fate in breast cancer patients
Anne-Lise Børresen-Dale, Norwegian Radium Hospital, Oslo, Norway

Amplifying the apoptotic actions of estrogen to treat metastatic breast cancer
V. Craig Jordan, Lombardi Comprehensive Cancer Center, Washington, DC, USA

Poster Session A

10:30 a.m.–12:30 p.m.

Networking Break

12:30 p.m.–2:00 p.m.

Concurrent Sessions

2:00 p.m.–4:00 p.m.

  • Session 1: Mutations in Malignancy

    Chairperson: Marco A. Pierotti, National Cancer Institute, Milan, Italy

    Target mutation: The dark site of the targeted therapies
    Marco A. Pierotti, National Tumor Institute, Milan, Italy

    Genetic alterations in melanoma: Implications for disease classification and therapy stratification
    Boris C. Bastian, UCSF Comprehensive Cancer Center, San Francisco, CA

    Mutations and expression profile to guide treatment in sarcomas and GIST
    Jean-Yves Blay, INSERM U-453, Lyon, France

  • Session 2: Immunotherapy

    Chairperson: Cornelis J.M. Melief, University Hospital Leiden, Leiden, The Netherlands

    Personalized chemotherapy of cancer based on immune parameters
    Laurence Zitvogel, Institut Gustave-Roussy, Villejuif, France

    Adoptive T cell transfer: Autografting cultured, specific T cells to treat cancer
    James Chung-Yin Yang, National Cancer Institute, Bethesda, MD, USA

    Development of therapeutic cancer vaccine and construction of clinical research network in Japan
    Yusuke Nakamura, University of Tokyo Human Genome Center, Tokyo, Japan

Plenary Session 2: Translational Medicine in Lung Cancer Research

Chairperson: Guiseppe Giaccone, National Cancer Institute, Bethesda, MD, USA
4:15 p.m.-6:15 p.m.

The impact of genomic changes on the treatment of lung cancer
Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA, USA

The genomic landscape in lung cancer
Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias I Pujol, Barcelona, Spain

Small cell lung cancer: A forgotten disease?
Giuseppe Giaccone, National Cancer Institute, Bethesda, MD, USA

 

TUESDAY, MARCH 23

Plenary Session 3: Translational Medicine in Multiple Myeloma

Chairperson: Jesús F. San Miguel, University of Salamanca, Salamanca, Spain
8:30 a.m.–10:30 a.m.

Biology of myeloma: Basis for novel drugs
Jesús F. San Miguel

Translating multiple myeloma stem cells
William H. Matsui, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Targeting the ubiquitin-proteasome pathway in myeloma therapy
Robert Z. Orlowski, UT M. D. Anderson Cancer Center, Houston, TX, USA

Poster Session B

10:30 a.m.–12:30 p.m.

Concurrent Sessions

1:30 p.m.-3:30 p.m.

  • Session 3: Circulating Tumor Cells and Stem Cells

    Chairperson: Howard I. Scher, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Detection, clinical relevance, and molecular characteristics of circulating tumor cells
    Klaus Pantel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Enumeration and characterization of CTCs
    Stefan Sleijfer, Erasmus Medical Center, Rotterdam, The Netherlands

    Molecular analysis of single disseminated tumor cells
    Christoph A. Klein, University of Regensburg, Regensburg, Germany

    Molecular characterization of circulating tumor cells in breast cancer
    Minetta C. Liu, Lombardi Comprehensive Cancer Center, Washington, DC, USA

  • Session 4: Pharmacogenomics, Drug Resistance, and Toxicity

    Chairperson: Eddie Reed, University of South Alabama, Mobile, AL, USA

    Pharmacogenetic considerations with molecularly targeted therapy
    Sharyn D. Baker, St. Jude Children's Research Hospital, Memphis, TN, USA

    Genome-wide discovery and clinical validation of pharmacogenomic markers for chemotherapy
    R. Stephanie Huang, University of Chicago, Chicago, IL, USA

    Genetic polymorphisms of ABC transporters in cancer chemotherapy: Development of SmartAmp2 method for clinical genetic testing
    Toshihisa Ishikawa, RIKEN Yokohama Institute, Yokohama, Japan

    Factors that influence the regulation of ERCC1 in drug resistant cells
    Eddie Reed

Plenary Session 4: Immunotherapy: Vaccines

Chairperson: Laurence Zitvogel, Institute Gustave-Roussy, Villejuif, France
4:00 p.m.–6:30 p.m.

Immunostimulation versus immunosuppresion: The woes of cancer vaccine development
Alexander M.M. Eggermont, Erasmus Medical Center, Rotterdam, The Netherlands

Therapeutic vaccines for prostate cancer
James L. Gulley, National Cancer Institute, Bethesda, MD, USA

Augmenting the immune response to prostate cancer with CTLA-4 blockade
Eric J. Small, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

A new era for dendritic cell vaccines
Gerold Schuler, University Hospital of Erlangen, Erlangen, Germany

Immunotherapy of established lesions caused by high-risk HPV
Cornelis J.M. Melief, University Hospital Leiden, Leiden, The Netherlands

 

WEDNESDAY, MARCH 24

Plenary Session 5: Targets Across Tumor Types

Chairperson: Keith T. Flaherty, Massachusetts General Hospital, Boston, MA, USA
8:30 a.m.-10:30 a.m.

Targeting the nexus of heat shock and metabolic stress responses in cancer
Kapil N. Bhalla, Medical College of Georgia, Augusta, GA, USA

BRAF mutant melanoma as the proving ground for the MAP kinase pathway as a therapeutic target
Keith T. Flaherty

Hedgehog pathway inhibitors in cancer
Josina C. Reddy, Genentech, Inc., South San Francisco, CA, USA

Targeting DNA repair mechanisms
E. Ruth Plummer, Northern Centre for Cancer Treatment, Newcastle upon Tyne, United Kingdom

Plenary Session 6: Resistance to Targeted Therapies

Chairperson: Tito Fojo, National Cancer Institute-DHHS, Bethesda, MD, USA
10:45 a.m.-12:45 p.m.

Resistance to targeted therapies in a realistic mouse breast cancer model
Piet Borst, Netherlands Cancer Institute, Amsterdam, The Netherlands

Resistance to VEGF-targeted therapies
Napoleone Ferrara, Genentech, Inc., South San Francisco, CA, USA

Antibody-initiated cancer immunotherapy
Louis M. Weiner, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA

Title to be announced
Howard I. Scher, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Plenary Session 7: Epigenetics

Chairperson: Susan E. Bates, National Cancer Institute, Bethesda, MD, USA
2:00 p.m.-4:00 p.m.

Cancer epigenetics: From DNA methylation to microRNAs
Manel Esteller, Hospital Duran i Reynals, Barcelona, Spain

Targeting histone methyl transferase and demethylases in cancer
Kristian Helin, University of Copenhagen, Copenhagen, Denmark

HDAC inhibitor activity in lymphomas and resistance in solid tumors: Overcoming the impasse
Susan E. Bates

Departure